Fibrinogen degradation products in serum from patients with cancer.
D000614:Aminocaproates / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D001943:Breast Neoplasms / Q000097:blood*; D003110:Colonic Neoplasms / Q000097:blood; D005260:Female; D005337:Fibrin / Q000378:metabolism*; D005340:Fibrinogen / Q000378:metabolism*; D005342:Fibrinolysis / Q000187:drug effects; D005770:Gastrointestinal Neoplasms / Q000097:blood*; D006801:Humans; D007122:Immunoelectrophoresis; D007414:Intestinal Neoplasms / Q000097:blood*; D007680:Kidney Neoplasms / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood*; D008207:Lymphatic Metastasis; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010190:Pancreatic Neoplasms / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood; D012004:Rectal Neoplasms / Q000097:blood; D013917:Thrombin / Q000494:pharmacology; D001749:Urinary Bladder Neoplasms / Q000097:blood; D014565:Urogenital Neoplasms / Q000097:blood*
D000614:Aminocaproates; D005337:Fibrin; D005340:Fibrinogen; D013917:Thrombin